However, our results indicate that compared to adjacent nontumor samples, CFL2 is downregulated at both the mRNA and protein levels in IGC patient tumors, similar to what was observed in pancreatic cancer [75]. This evidence concerns the gene CFL2 and pancreatic neoplasm.